Patient IDSexAge Pathology Nephrectomy MSKCC classification NCCN classification Prior therapy SUVmaxSUVmax site typegrading 1M58unknown NoPoor non13.3lung.

Slides:



Advertisements
Similar presentations
CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.
Advertisements

Michele Milella Oncologia Medica A Istituto Nazionale Tumori Regina Elena Roma.
The long term outcome of high risk non-muscle invasive bladder cancer. F Thomas, N Rubin, J Goepel, D Rosario, MF Abbod, JWF Catto. Academic unit of Urology,
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.
PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.
the Cox proportional hazards model (Cox Regression Model)
LARGE SAMPLE TESTS ON PROPORTIONS
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Introduction MarkerPolymorphisms in CYP2C19 (*2 and *17) assessed by Taqman allelic discrimination ObjectivesTo evaluate the predictive capacity of CYP2C19.
Estimating cancer survival and clinical outcome based on genetic tumor progression scores Jörg Rahnenführer 1,*, Niko Beerenwinkel 1,, Wolfgang A. Schulz.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Lymphadenectomy in Epithelial Ovarian Cancer
Confidence Intervals Elizabeth Garrett-Mayer
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma Luigi Marcheselli, Raffaella Marcheselli, Alessia Bari, Eliana.
Renal cell cancer: Integrating novel agents into a therapeutic algorithm Robert Dreicer, M.D., FACP Chairman Department of Solid Tumor Oncology Taussig.
Renal Tumor Dr. Abdullah A. Ghazi (R4) 23/4/2011 Half day resident activity.
Does the embolization of the tumor, prior to radical nephrectomy, prologs the life of patients with renal cell carcinoma * Department of Urology Regional.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
Predicting toxicity for patients with advanced Gastrointestinal Stromal Tumors (GIST) treated with imatinib mesylate : an EORTC/ISG/AGITG randomized trial.
Thyroid Debate (Papillary Thyroid Cancer: Extent of Thyroidectomy) 30 Aug 2007 Surgery-OMMC JGGuerra, MD HCruz, MD.
Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
Breast Cancer in the Women’s Health Initiative Trial of Estrogen Plus Progestin For the WHI Investigators Rowan T Chlebowski, MD., Ph.D.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.
Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.
Overall summary of missing values VariablesCasesValues Supplementary Figure 1. Overall summary of missing values. Variables represents the ratio of missing.
Lecture 4 Confidence Intervals. Lecture Summary Last lecture, we talked about summary statistics and how “good” they were in estimating the parameters.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
ASCO 2009 BEVACIZUMAB IN METASTATIC RENAL CELL CARCINOMA: An Update of the CALGB and AVOREN Trials Reviewed by: Dr. Daniel.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Renal cell carcinoma R4 신재령 Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma.
Javier Martin-Broto, Silvia Calabuig, Jordi Rubió, Antonio Gutierrez, José Duran, Florencia García, Javier Martinez Trufero, Joan Maurel, Xavier García.
소화기내과 김경엽 Gastroenterology 2011;140:
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
ALBUMIN IS AN EFFECT MODIFIER IN THE RELATIONSHIP BETWEEN ERYTHROPOIETIN STIMULATING AGENT AND MORTALITY IN HEMODIALYSIS PATIENTS. Satoshi Mikami1, Takayuki.
Volume 60, Issue 5, Pages (November 2011)
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
Copyright © 2008 American Medical Association. All rights reserved.
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Final results of the phase III, randomised, double-blind AVOREN trial of first-line bevacizumab + interferon-a2a in metastatic renal cell carcinoma Escudier.
A B HMS derived in HNSCC HMS derived in BC c) HR for MFS [NKI data]
Mahmood rasheed Hematology/oncology fellow VCU Massey cancer center
Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer  Christina K. Speirs, MD, PhD, Todd.
Patients who have received chemotherapy (n=60)
Disease-specific survival
Published online September 20, 2017 by JAMA Surgery
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
高雄榮民總醫院耳鼻喉頭頸部 林陞樵 林曜祥 康柏皇 張庭碩
High CDK6 expression predicts poor prognosis in EOC patients
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
CUP is a clinico-pathological syndrome of many specific cancer
OS by OR for the Sorafenib plus HAIC Group
Cumulative mortality risk in patients with 48-h blood urea nitrogen (BUN) levels of ≥8 mg/dl or
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.
median of follow-up (month)
Presentation transcript:

Patient IDSexAge Pathology Nephrectomy MSKCC classification NCCN classification Prior therapy SUVmaxSUVmax site typegrading 1M58unknown NoPoor non13.3lung 2M63sarc / clear3YesPoor IFN15.2local recurrence 3M73clear2YesFavorableNot PoorIFN IL8.2lung 4M61papillary3NoIntermediate Poornon8.8primary 5F72clear1NoIntermediateNot Poornon5.2primary 6F55clear2NoIntermediateNot PoorIFN IL6.8primary 7M57papillary2YesIntermediate PoorN4.0bone 8M59clear2YesIntermediate Poornon7.4bone 9M68clear3YesIntermediateNot PoorIFN5.7bone 10F57clear2YesPoor IFN N9.1lymph node 11M75clear2YesIntermediateNot PoorIFN5.3muscle 12M58clear3YesFavorableNot PoorIFN8.5local recurrence 13F61clear2YesIntermediate PoorIFN C4.3pancreas 14M59clear2YesIntermediateNot Poornon1.4lung 15M61clear2YesIntermediatePoorIFN7.7lymph node 16M73clear2NoPoor non16.6primary 17F32papillary3YesFavorableNot Poornon16.1uterus 18M56papillary2YesIntermediateNot PoorC7.0lung 19M68clear2YesIntermediatePoornon9.0bone 20M61clear2YesIntermediateNot Poornon5.6IVC thrombus 21F56sarc /clear3YesIntermediate PoorIFN10.0 contralateral kidney 22M62clear3NoPoor non12.0primary 23M61clear3NoPoor non14.3primary 24M82clear1YesIntermediate Poornon5.1bone 25M69papillary3YesFavorableNot Poornon13.4lymph node 26M66clear1YesIntermediateNot PoorIFN8.2lung Table 1. Characteristics of the 26 patients

Table 2. Univariate and multivariate Cox survival analyses of SUVmax and various clinical parameters 95% CIs P value Risk Factors SUVmax (continuous variable) PS (<80%) LDH(>1.5x upper limit of normal) Ca (>10mg/dl) Nephrectomy (no) Hb (<lower limit of normal) Interval (<1 year) Metastatic site (>2) HR P value X HR %CIs Univariate analysis Multivariate analysis* *Cox multivariate model with backward elimination procedures was applied for SUVmax, PS, LDH, Ca and Nephrectomy. The p-value of variables not statistically significantly associated with survival in the best Cox model are indicated by an X.

Table 3. Univariate and Multivariate Cox Analyses of SUVmax versus Standard Prognostic Classification for Advanced RCC Risk factors SUVmax (continuous variable) MSKCC classification* NCCN classification** *Poor risk vs Favorable risk/Intermediate risk **Poor risk vs not poor risk ***multivariate analysis was performed using SUVmax and MSKCC classification HR P-value %CIs HR P-value %CIs Univariate analysis Multivariate analysis ***